Recent developments in Neisseria meningitidis group A conjugate vaccines

Expert Opinion on Biological Therapy

Volumn 5, Issue 2, 2005, Pages 273-280

  Frasch, Carl E ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

Bacterial vaccine; Conjugate vaccine; Meningitis; Meningococcus; Neisseria meningitidis; Polysaccharide

Indexed keywords

BACTERIAL VACCINE; BACTERIUM ANTIBODY; POLYSACCHARIDE; POLYSACCHARIDE VACCINE; VACCINE;

AFRICA; COST EFFECTIVENESS ANALYSIS; DEVELOPING COUNTRY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; MENINGITIS; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; NONHUMAN; REVIEW; UNITED KINGDOM; VACCINE PRODUCTION;

ANIMALS; HUMANS; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP A; TECHNOLOGY, PHARMACEUTICAL; VACCINES, CONJUGATE;

EID: 15244357239     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.5.2.273     Document Type: Review

References (42)

1. FRASCH CE: Production and control of Neisseria meningitidis vaccines. In: Bacterial Vaccines. Mizrahi A (Ed.), Wiley-Liss, New York, USA (1990):123-145.
2. FRASCH CE: Meningococcal vaccines: past, present and future. In: Meningococcal Disease. Cartwright K (Ed.), Wiley, New York, USA (1995):245-283.
3. ZOLLINGER WD: New and improved vaccines against meningococcal disease. In: New Generation Vaccines. Levine MM, Woodrow GC, Kaper JB, Cobon GS (Eds), Marcel Dekker, New York, USA (1997):469-488.
4. FRASCH CE, BASH MC: Neisseria meningitis vaccines. In: Bacterial Vaccines. Ellis RW, Brodeur BR (Eds), Eurekah, New York, USA (2003):228-242.
5. JODAR L, FEAVERS IM, SALISBURY D, GRANOFF DM: Development of vaccines against meningococcal disease. Lancet (2002) 359:1499-1508. Provides a good overview of recent meningococcal vaccine development.
6. GOLDSCHNEIDER I, GOTSCHLICH EC, ARTENSTEIN MS: Human immunity to the meningococcus. II. Development of natutal immunity. J. Exp. Med. (1969) 129:1327-1348.
7. LENNON D, GELLIN B, HOOD D et al.: Successful intervention in a Group A meningococcal outbreak in Auckland, New Zealand. Pediatr. Infect. Dis. J. (1992) 11:617-623.
8. KÄYHTY H, PELTOLA H, ESKOLA J et al.: Immunogenicity of Haemophilus influenzae oligosaccharide- protein and polysaccharide-protein conjugate vaccination of children at 4, 6, and 14 months of age. Pediatrics (1989) 84:995-999.
9. WARD J, BRENNEMAN G, LETSON GW, HEYWARD WL, ALASKA H: Limited efficacy of a Haemophilus influenzae type b conjugate vaccine in Alaska Native infants. Influenzae Vaccine Group. N. Engl. J. Med. (1990) 323:1393-1401.
10. TROTTER CL, ANDREWS NJ, KACZMARSKI EB, MILLER E, RAMSEY ME: Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet (2004) 364:365-367. Excellent update of conjugate effectiveness for up to 4 years and the importance of antibody versus memory.
11. BORROW R, GOLDBLATT D, ANDREWS N et al.: Antibody persistence and immunological memory at age 4 years after meningococcal group C conjugate vaccination in children in the United Kingdom. J. Infect. Dis. (2002) 186:1353-1357.
12. PELTOLA H, MAKELA PH, KAYHTY H et al.: Clinical efficacy of meningococcus group a capsular polysaccharide vaccine in children three months to five years of age. N. Engl. J. Med. (1977) 297:686-691.
13. SCHNEERSON R, BARRERA O, SUTTON A, ROBBINS JB: Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide protein conjugates. J. Exp. Med. (1980) 152:361-376.
14. BISGARD KM, KAO A, LEAKE J et al.: Haemophilus influenzae invasive disease in the United States, 1994-1995: near disappearance of a vaccine-preventable childhood disease. Emerg. Infect. Dis. (1998) 4:1-14.
15. BEUVERY EC, KAADEN AVD, KANHAI V, LEUSSINK AB: Physiochemical and immunological characterization of meningococcal group A polysaccharide-tetanus toxoid conjugates prepared by two methods. Vaccine (1983) 1:31-36.
16. JENNINGS HJ, LUGOWSKI C: Immunochemistry of groups A, B, and C meningococcal polysaccharide-tetanus toxoid conjugates. J. Immunol. (1981) 127:1011-1018.
17. BERRY DS, LYNN F, LEE CH, FRASCH CE, BASH MC: Effect of O acetylation of Neisseria meningitidis serogroup A capsular polysaccharide on development of functional immune responses. Infect. Immun. (2002) 70:3707-3713.
18. BEUVERY EC, DELFT RV, MIEDEMA F, KANHAI V, NAGEL J: Immunological evaluation of meningococcal group C polysaccharide-tetanus toxoid conjugate in mice. Infect. Immun. (1983) 41:609-617.
19. COSTANTINO P, VITI S, PODDA A et al.: Development and Phase I clinical testing of a conjugate vaccine against meningococcus A and C. Vaccine (1992) 10:691-698.
20. ANDERSON EL, BOWERS T, MINK CM et al.: Safety and immunogenicity of meningococcal A and C polysaccharide conjugate vaccine in adults. Infect. Immun. (1994) 62:3391-3395.
21. LIEBERMAN JM, CHIU SS, WONG VK et al.: Safety and immunogenicity of a serogroups A/C Neisseria meningitidis oligosaccharide-protein conjugate vaccine in young children - a randomized controlled trial. JAMA (1996) 275:1499-1503.
22. TWUMASI PA JR, KUMAH S, LEACH A et al.: A trial of a group A plus group C meningococcal polysaccharide- protein conjugate vaccine in African infants. J. Infect. Dis. (1995) 171:632-638. First meningococcal conjugate vaccine trial in West Africa.
23. FAIRLEY CK, BEGG N, BORROW R et al.: Conjugate meningococcal serogroup A and C vaccine: reactogenicity and immunogenicity in United Kingdom infants. J. Infect. Dis. (1996) 174:1360-1363.
24. LEACH A, TWUMASI PA, KUMAH S et al.: Induction of immunologic memory in gambian children by vaccination in infancy with a group A plus group C meningococcal polysaccharide- protein conjugate vaccine. J. Infect. Dis. (1997) 175:200-204.
25. MACLENNAN J, OBARO S, DEEKS J et al.: Immunologic memory 5 years after meningococcal A/C conjugate vaccination in infancy. J. Infect. Dis. (2001) 183:97-104.
26. HARRIS SL, FINN A, GRANOFF DM: Disparity in functional activity between serum anticapsular antibodies induced in adults by immunization with an investigational group A and C Neisseria meningitidis-diphtheria toxoid conjugate vaccine and by a polysaccharide vaccine. Infect. Immun. (2003) 71:3402-3408.
27. CAMPAGNE G, GARBA A, FABRE P et al.: Safety and immunogenicity of three doses of a Neisseria meningitidis A+C diphtheria conjugate vaccine in infants from Niger. Pediatr. Infect. Dis. J. (2000) 19:144-150.
28. LAGOS R, VALENZUELA MT, LEVINE OS et al.: Economisation of vaccination against Haemophilus influenzae type b: a randomised trial of immunoaffinity of fractional-dose and two-dose regimens. Lancet (1998) 351:1472-1476.
29. CHIPPAUX JP, GARBA A, ETHEVENAUX C et al.: Immunogenicity, safety, and memory of different schedules of Neisseria meningitidis A/C-diphtheria toxoid conjugate vaccine infants in Niger. Vaccine (2004) 22:3303-3311.
30. JOSEPH H, RYALL R, BYBEL M et al.: Immunogenicity and immunological priming of the serogroup A portion of a bivalent meningococcal A/C conjugate vaccine in 2-year-old children. J Infect. Dis. (2003) 187:1142-1146.
31. ZHANG Q, LAKSHMAN R, BURKINSHAW R et al.: Primary and booster mucosal immune responses to meningococcal group A and C conjugate and polysaccharide vaccines administered to university students in the United Kingdom. Infect. Immun. (2001) 69:4337-4341.
32. MAIDEN MC, STUART JM, UK MENINGOCOCCAL CARRIAGE GROUP: Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet (2002) 359:1829-1830.
33. CAMPBELL JD, EDELMAN R, KING JC JR et al.: Safety, reactogenicity, and immunogenicity of a tetravalent meningococcal polysaccharide-diphtheria toxoid conjugate vaccine given to healthy adults. J Infect. Dis. (2002) 186:1848-1851.
34. RENNELS M, KING J JR, RYALL R et al.: Dose escalation, safety and immunogenicity study of a tetravalent meningococcal polysaccharide diphtheria conjugate vaccine in toddlers. Pediatr. Infect. Dis. J. (2002) 21:978-979.
35. RENNELS M, KING J JR, RYALL R, PAPA T, FROESCHLE J: dosage escalation, safety and immunogenicity study of four dosages of a tetravalent meningococcal polysaccharide diphtheria toxoid conjugate vaccine in infants. Pediatr. Infect. Dis. J. (2004) 23:429-435. First reported infant studies with existing tetravalent meningococcal conjugate vaccine.
36. ROBBINS JB, SCHNEERSON R, GOTSCHLICH E et al.: Meningococcal meningitis in sub-Saharan Africa: the case for mass and routine vaccination with available polysaccharide vaccines. Bull. World Health Organ. (2003) 81:745-750. Documents the strengths of different approaches for the prevention of epidemic meningitis in sub-Saharan Africa.
37. LAFORCE FM: Control of epidemic meningitis in sub-Saharan Africa: our solution is more practical and affordable. Bull. World Health Organ. (2003) 81:753-754. Documents the strengths of different approaches for the prevention of epidemic meningitis in sub-Saharan Africa.
38. ROBBINS JB, SCHNEERSON R, GOTSCHLICH EC: A rebuttal: epidemic and endemic meningococcal. meningitis in sub-Saharan Africa can be prevented now by routine immunization with group A meningococcal capsular polysaccharide vaccine. Pediatr. Infect. Dis. J. (2000) 19:945-953.
39. CHIPPAUX JP, DEBOIS H, SALIOU P: A critical review of control strategies against meningococcal meningitis epidemics in sub-Saharan African countries. Infection (2002) 30:216-224.
40. ROBBINS JB, TOWNE DW, GOTSCHLICH EC, SCHNEERSON R: 'Loves labours lost': failure to implement mass vaccination against group A meningococcal meningitis in sub-Saharan Africa. Lancet (1997) 350:880-882.
41. MILLER E, SALISBURY D, RAMSAY M: Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine (2001) 20(Suppl. 1):S58-S67. Provides a road-map for licensure of a new vaccine for which the mechanism of protection is understood.
42. JODAR L, LAFORCE FM, CECCARINI C, AGUADO T, GRANOFF DM: Meningococcal conjugate vaccine for Africa: a model for development of new vaccines for the poorest countries. Lancet (2003) 361:1902-1904. A new paradigm for how vaccines may be produced.